A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor in Pediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease (HOPE Kids 2)

About this Study

The primary objective of Part A of this study is to assess the efficacy of voxelotor with long term, daily dosing compared to placebo in pediatric participants with SCD as measured by improvement in anemia.

Sponsor Protocol ID:GBT440-032
IRB Number:2020V0170
Actively Enrolling
Interventional
Phase 3
October 26, 2021
Eligibility Criteria
2 years old
12 years old
Both Male and Female
No
Yes
No

Inclusion Criteria1. Age 2 to

2. Participants, who if female and of child bearing potential, are using highly effective methods of contraception from study start to 30 days after the last dose of study drug, and who if male are willing to use barrier methods of contraception, from study start to 30 days after the last dose of study drug.

3. Females of child-bearing potential are required to have a negative pregnancy test before randomization.

Exclusion Criteria1. Body weight

2.  Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine.

3. Parent or legal guardian/participants are unlikely to comply with the study procedures.

4. Other medical, psychological or addictive condition that, in the opinion of the Investigator, would: confound or interfere with evaluation of safety, efficacy and/or PK of the investigational drug; prevent compliance with the study protocol; preclude informed consent; or, render the participant, parent, or caretaker unable/unlikely to comply with the study procedures.

Categories Click category to view its trials.
Pediatrics
Participating Locations
Children’s of Mississippi - Batson Kids Clinic
Contact Information
Contact Name: Jennifer Williams
Phone Number: 601-815-9295
Email: jnwilliams@umc.edu
Principal Investigator:Mcnaull, Melissa A, M.D.
How to participate in our Clinical Trials